CVS Health to restore Zepbound coverage and add Eli Lilly's new obesity pill to drug plans
By
Annika Kim Constantino
3d ago· 3 min readenNews
80/100
Golden Brown
Bagelometer↗
Slow-proofed and worth the wait. Worth its weight in flour.
Score80TypenewsSentimentpositive
Summary
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and add coverage of Lilly's newly approved Foundayo pill starting June 1 to its standard drug plans. This move comes a year after CVS removed Zepbound from its coverage, and it positions both Lilly and Novo Nordisk on equal footing in major drug plans. The decision is a significant win for Eli Lilly as it competes with Novo Nordisk in the lucrative weight loss drug market, and it expands treatment access for patients.
Key quotes
· 3 pulledCVS Health on Thursday said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans – a win for the drugmaker and certain patients who will be able to access more treatment options.
The move will boost Lilly's efforts to maintain its dominance over Novo Nordisk in the blockbuster weight loss drug market, as it puts the two drugmakers on equal footing in major plans.
It comes a year after CVS st
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
